BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 75,000 shares of the firm's stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $34.11, for a total transaction of $2,558,250.00. Following the completion of the transaction, the chief executive officer now owns 4,873,447 shares of the company's stock, valued at approximately $166,233,277.17. This trade represents a 1.52 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Neil Kumar also recently made the following trade(s):
- On Tuesday, March 25th, Neil Kumar sold 75,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $36.87, for a total transaction of $2,765,250.00.
- On Tuesday, February 25th, Neil Kumar sold 75,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $33.57, for a total transaction of $2,517,750.00.
- On Wednesday, February 19th, Neil Kumar sold 31,543 shares of BridgeBio Pharma stock. The stock was sold at an average price of $36.14, for a total value of $1,139,964.02.
- On Tuesday, January 28th, Neil Kumar sold 326,932 shares of BridgeBio Pharma stock. The shares were sold at an average price of $36.29, for a total value of $11,864,362.28.
BridgeBio Pharma Price Performance
BBIO stock opened at $35.96 on Friday. BridgeBio Pharma, Inc. has a 1 year low of $21.62 and a 1 year high of $39.47. The stock has a market capitalization of $6.83 billion, a PE ratio of -12.62 and a beta of 1.08. The company's 50-day moving average is $33.90 and its 200-day moving average is $30.34.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million during the quarter, compared to analysts' expectations of $4.04 million. On average, analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several brokerages recently commented on BBIO. JPMorgan Chase & Co. upped their target price on BridgeBio Pharma from $44.00 to $50.00 and gave the company an "overweight" rating in a report on Monday, March 24th. Citigroup upped their price objective on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the company a "buy" rating in a research note on Friday, February 21st. HC Wainwright lifted their target price on shares of BridgeBio Pharma from $49.00 to $53.00 and gave the stock a "buy" rating in a research note on Tuesday, April 15th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $95.00 price target on shares of BridgeBio Pharma in a research report on Friday, February 21st. Finally, Scotiabank lifted their price objective on BridgeBio Pharma from $49.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Friday, February 21st. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $53.00.
Check Out Our Latest Report on BBIO
Institutional Trading of BridgeBio Pharma
Hedge funds have recently bought and sold shares of the business. Barclays PLC lifted its stake in shares of BridgeBio Pharma by 31.9% in the third quarter. Barclays PLC now owns 545,008 shares of the company's stock valued at $13,876,000 after buying an additional 131,743 shares in the last quarter. Exome Asset Management LLC lifted its position in BridgeBio Pharma by 167.4% in the 3rd quarter. Exome Asset Management LLC now owns 211,000 shares of the company's stock valued at $5,372,000 after acquiring an additional 132,093 shares in the last quarter. Principal Financial Group Inc. lifted its position in BridgeBio Pharma by 1.8% in the 3rd quarter. Principal Financial Group Inc. now owns 1,145,123 shares of the company's stock valued at $29,155,000 after acquiring an additional 19,978 shares in the last quarter. Avanza Fonder AB acquired a new position in BridgeBio Pharma during the 4th quarter valued at about $181,000. Finally, Moss Adams Wealth Advisors LLC bought a new stake in BridgeBio Pharma during the 4th quarter worth approximately $208,000. Institutional investors and hedge funds own 99.85% of the company's stock.
BridgeBio Pharma Company Profile
(
Get Free Report)
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
